SCHEMBL4734136

SCHEMBL4734136

O=C(O)NC1CCN(C(=O)c2ccc(Cl)nc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.60
RAB9A P51151 1/20 0.56
PRKAA2 P54646 5/20 0.52
PRKAB2 O43741 3/20 0.52
PRKAG1 P54619 3/20 0.52
PRKAA1 Q13131 3/20 0.52
PRKAG3 Q9UGI9 3/20 0.52
PRKAG2 Q9UGJ0 3/20 0.52
PRKAB1 Q9Y478 3/20 0.52
EPHX1 P07099 2/20 0.51
HPGD P15428 1/20 0.50
SFRP1 Q8N474 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
GRM5 P41594 1/20 0.47
NAPRT Q6XQN6 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13202942 0.85 RAB9A (0.57) EPHX2RAB9APRKAA2PRKAB2PRKAG1
SCHEMBL4616966 0.83 EPHX2 (0.59) EPHX2RAB9APRKAA2PRKAB2PRKAG1
SCHEMBL4534421 0.82 MAPT (0.67) EPHX2RAB9AHPGDSMN1; SMN2GRM5
SCHEMBL4617713 0.82 GFER (0.53) EPHX2EPHX1MEN1KMT2A
SCHEMBL23573470 0.81 SFRP1 (0.57) EPHX2PRKAA2PRKAB2PRKAG1PRKAA1
SCHEMBL6102058 0.81 HPGDS (0.57) EPHX2PRKAA2PRKAB2PRKAG1PRKAA1
SCHEMBL4736618 0.81 RAB9A (0.58) EPHX2RAB9AHPGDSFRP1SMN1; SMN2
SCHEMBL8434306 0.80 RAB9A (0.64) EPHX2RAB9AHPGDSMN1; SMN2GRM5
SCHEMBL16973635 0.80 PRKAA2 (0.44) EPHX2PRKAA2PRKAB2PRKAG1PRKAA1
SCHEMBL2001638 0.78 AKR1C3 (0.50) EPHX2PRKAA2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210198239-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR PLEXXIKON INC. 2021-07-01 US disclosed
WO-2008061016-A1 N-SUBSTITUTED PIPERIDINYL 4 -ARYLSULFONAMIDES AS MODULATORS OF THE SECRETED FRIZZLED RELATED PROTEIN- 1 WYETH (US) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210198239-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR ENTPD5, ADORA2A, ENTPD1 EPHX2 959/4885RAB9A 2930/4885PRKAA2 2641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.